These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 30328552)

  • 1. Gonadal Hormones in the Pathogenesis and Treatment of Bone Health in Patients with Chronic Kidney Disease: a Systematic Review and Meta-Analysis.
    Aleksova J; Rodriguez AJ; McLachlan R; Kerr P; Milat F; Ebeling PR
    Curr Osteoporos Rep; 2018 Dec; 16(6):674-692. PubMed ID: 30328552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.
    Bover J; Bailone L; López-Báez V; Benito S; Ciceri P; Galassi A; Cozzolino M
    J Nephrol; 2017 Oct; 30(5):677-687. PubMed ID: 28432640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis.
    Wilson LM; Rebholz CM; Jirru E; Liu MC; Zhang A; Gayleard J; Chu Y; Robinson KA
    Ann Intern Med; 2017 May; 166(9):649-658. PubMed ID: 28395318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease-chronic kidney disease-mineral and bone disorder: osteoporosis.
    Lee WL; Cheng MH; Tarng DC; Yang WC; Lee FK; Wang PH
    J Chin Med Assoc; 2013 Jul; 76(7):365-71. PubMed ID: 23664736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low bone mineral density and fractures in stages 3-5 CKD: an updated systematic review and meta-analysis.
    Bucur RC; Panjwani DD; Turner L; Rader T; West SL; Jamal SA
    Osteoporos Int; 2015 Feb; 26(2):449-58. PubMed ID: 25477230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy for patients with CKD and low bone mineral density.
    Ott SM
    Nat Rev Nephrol; 2013 Nov; 9(11):681-92. PubMed ID: 24100401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.
    Segaud N; Legroux I; Hazzan M; Noel C; Cortet B
    Osteoporos Int; 2018 May; 29(5):1165-1175. PubMed ID: 29500526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fracture risk and treatment in chronic kidney disease.
    Connelly K; Collister D; Tangri N
    Curr Opin Nephrol Hypertens; 2018 May; 27(3):221-225. PubMed ID: 29547405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex hormone-binding globulin is a biomarker associated with nonvertebral fracture in men on dialysis therapy.
    Aleksova J; Wong P; McLachlan R; Choy KW; Ebeling PR; Milat F; Elder GJ
    Kidney Int; 2018 Aug; 94(2):372-380. PubMed ID: 29776756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
    O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
    Cochrane Database Syst Rev; 2006 Jul; (3):CD005326. PubMed ID: 16856092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interventions for the treatment of decreased bone mineral density associated with HIV infection.
    Lin D; Rieder MJ
    Cochrane Database Syst Rev; 2007 Apr; (2):CD005645. PubMed ID: 17443607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of medications for osteoporosis in kidney transplant recipients or patients with chronic kidney disease: A meta-analysis.
    Leng Y; Yu X; Yang Y; Xia Y
    J Investig Med; 2023 Oct; 71(7):760-772. PubMed ID: 37387531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updates in CKD-Associated Osteoporosis.
    Khairallah P; Nickolas TL
    Curr Osteoporos Rep; 2018 Dec; 16(6):712-723. PubMed ID: 30353319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The treatment of the patient presenting with chronic kidney disease (CKD) and fragility fractures].
    Giusti A; Fusaro M
    G Ital Nefrol; 2017 Dec; 34(Nov-Dec):. PubMed ID: 29207226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B-5) chronic kidney disease: an open cohort multivariable and propensity score analysis from Funen, Denmark.
    Ali MS; Ernst M; Robinson DE; Caskey F; Arden NK; Ben-Shlomo Y; Nybo M; Rubin KH; Judge A; Cooper C; Javaid MK; Hermann AP; Prieto-Alhambra D
    Arch Osteoporos; 2020 Jun; 15(1):81. PubMed ID: 32483674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to predict and treat increased fracture risk in chronic kidney disease.
    West SL; Patel P; Jamal SA
    J Intern Med; 2015 Jul; 278(1):19-28. PubMed ID: 25758353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of walking for preservation of bone mineral density in postmenopausal women.
    Martyn-St James M; Carroll S
    Bone; 2008 Sep; 43(3):521-31. PubMed ID: 18602880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Osteoporosis treatment for patients with chronic kidney disease].
    Konishi Y
    Nihon Rinsho; 2015 Oct; 73(10):1723-7. PubMed ID: 26529937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5.
    Haghverdi F; Farbodara T; Mortaji S; Soltani P; Saidi N
    Iran J Kidney Dis; 2014 Nov; 8(6):461-6. PubMed ID: 25362221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
    Siris ES; Harris ST; Eastell R; Zanchetta JR; Goemaere S; Diez-Perez A; Stock JL; Song J; Qu Y; Kulkarni PM; Siddhanti SR; Wong M; Cummings SR;
    J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.